Previous 10 | Next 10 |
2024-05-09 17:13:21 ET More on Gilead Sciences, Arcellx Gilead Sciences, Inc. (GILD) Q1 2024 Earnings Call Transcript Gilead Sciences, Inc. 2024 Q1 - Results - Earnings Call Presentation Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern? Gi...
-- The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody -- -- Anito-cel will be manufactured from Kite’s Frederick, Maryland facility for iMMagine-3 as th...
NORTHAMPTON, MA / ACCESSWIRE / May 9, 2024 / A 22-year-old college student who didn't feel well was treated at an urgent care facility in Baton Rouge, Louisiana and expected to recover soon. But when his symptoms worsened, he returned to the emergency department and was given a more thorough che...
2024-05-07 20:26:14 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
NORTHAMPTON, MA / ACCESSWIRE / May 7, 2024 / James had been free from using drugs for a decade when a routine test at his local health center revealed he had hepatitis C (HCV). James was one of many people in the island nation of Mauritius to receive a diagnosis. After seeing a surge of cases t...
2024-05-07 09:01:37 ET Apple ( NASDAQ: AAPL ) recently updated its capital return plan by adding a $110B to its buyback program. According to data highlighted by Mizuho, this massive buyback program is larger than 84% of the stocks that sit inside the S&P 500.... Read ...
– Non-Small Cell Lung Cancer Development Program Data to be Presented, Including the Phase 3 EVOKE-01 Study – – Updated Results from Phase 2 EDGE-Gastric Study of Fc-Silent Anti-TIGIT Domvanalimab Plus A nti-PD-1 Zimberelimab, to be Presented ...
2024-05-04 15:30:00 ET Read the full article on Seeking Alpha For further details see: Pharma R&D productivity seen improving for the first time in years - Deloitte
NORTHAMPTON, MA / ACCESSWIRE / May 3, 2024 / Gilead Sciences Forbes has listed Gilead as one of America's Best Employers for Diversity. We believe that by championing inclusion and diversity, we not only enrich our workplace but also drive groundbreaking advancements in science. "Continuing ...
2024-05-01 14:38:49 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks are full of intriguing innovators who could help pave the way for greater gains over the years ahead. Undoubtedly, it’s virtually impossible to tell exactly which pill...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...